Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, Greig NH, Li Y, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ (2023) The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
The reduction was relatively selective for visceral adipose tissue the metabolically active fat packed around the abdominal organs while subcutaneous fat was not reduced to a clinically significant extent
In addition, it modulates the glutamatergic pathway and possesses anti-neurotic and antioxidant properties
Retatrutide is the lead triple agonist, hitting GLP-1, GIP, and glucagon receptors at once
